3-醛基水杨酸 | 610-04-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-醛基水杨酸
• 英文名称: 3-formylsalicylic acid
• 英文别名: 3-formyl-2-hydroxybenzoic acid
• CAS: 610-04-8
• 化学式: C₈H₆O₄
• mdl: MFCD00143165
• 分子量: 166.133
• InChiKey: YOEUNKPREOJHBW-UHFFFAOYSA-N

物化性质

• 熔点：
  177.5°C
• 沸点：
  214.32°C (rough estimate)
• 密度：
  1.2208 (rough estimate)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090
• 储存条件：
  室温、密闭保存，并确保干燥。

SDS

Name:	3-Formylsalicylic acid 97% Material Safety Data Sheet
Synonym:	None
CAS:	610-04-8

Section 1 - Chemical Product MSDS Name:3-Formylsalicylic acid 97% Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
610-04-8	3-Formylsalicylic acid	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause digestive tract disturbances. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. If irritation develops, get medical aid.
Skin:
Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical aid if irritation develops or persists. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam. Use agent most appropriate to extinguish fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash hands before eating. Avoid breathing dust, vapor, mist, or gas.
Avoid contact with skin and eyes. Keep container tightly closed. Use with adequate ventilation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits CAS# 610-04-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear a chemical apron. Wear appropriate clothing to prevent skin exposure.
Respirators:
A NIOSH/MSHA approved air purifying dust or mist respirator or European Standard EN 149. Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: acetic odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 180 - 183 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: N/A
Explosion Limits, upper: N/A
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H6O4
Molecular Weight: 166.13

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, moisture.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 610-04-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Formylsalicylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 610-04-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 610-04-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 610-04-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-醛基水杨酸 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以90%的产率得到3-bromo-5-formyl-6-hydroxybenzoic acid
  参考文献：
  名称：

  Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors

  摘要：

  HIV-1 integrase is one of the three most important enzymes required for viral replication and is therefore an attractive target for anti retroviral therapy. We herein report the design and synthesis of 3-keto salicylic acid chalcone derivatives as novel HIV-1 integrase inhibitors. The most active compound, 5-bromo-2-hydroxy-3-[3-(2,3,6-trichlorophenyl)acryloyl] benzoic acid (25) was selectively active against integrase strand transfer, with an IC50 of 3.7 mu M. While most of the compounds exhibited strand transfer selectivity, a few were nonselective, such as 5-bromo-3-[3-(4-bromophenyl)acryloyl]-2-hydroxybenzoic acid (15), which was active against both 3'-processing and strand transfer with IC50 values of 11 +/- 4 and 5 +/- 2 mu M, respectively. The compounds also inhibited HIV replication with potencies comparable with their integrase inhibitory potencies. Thus, 5-bromo-2-hydroxy-3-[3-(2,3,6-trichlorophenyl) acryloyl] benzoic acid (25) and 5-bromo-3-[3-(4-bromophenyl) acryloyl]-2-hydroxybenzoic acid (15) inhibited HIV-1 replication with EC50 values of 7.3 and 8.7 mu M, respectively. A PHASE pharmacophore hypothesis was developed and validated by 3D-QSAR, which gave a predictive r(2) of 0.57 for an external test set of ten compounds. Phamacophore derived molecular alignments were used for CoMFA and CoMSIA 3D-QSAR modeling. CoMSIA afforded the best model with q(2) and r(2) values of 0.54 and 0.94, respectively. This model predicted all the ten compounds of the test set within 0.56 log units of the actual pIC(50) values; and can be used to guide the rational design of more potent novel 3-keto salicylic acid integrase inhibitors (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.01.047
• 作为产物：
  描述：

  水杨酸 在 盐酸 作用下， 以 水 为溶剂， 反应 19.0h， 生成 3-醛基水杨酸
  参考文献：
  名称：

  A novel sensitive and selective chemosensor for fluorescent detection of Zn²⁺ in cosmetics creams based on a covalent post functionalized Al-MOF

  摘要：

  基于席夫碱反应制备了一种材料，以实现NH₂-MIL-53(Al)和3-甲醛基水杨酸的共价连接，用于基于CN异构化和ESIPT的抑制和破坏来荧光检测Zn²⁺离子。

  DOI：

  10.1039/d1nj00871d

文献信息

• Small-molecules that covalently react with a human prolyl hydroxylase – towards activity modulation and substrate capture
  作者：Jacob T. Bush、Robert K. Leśniak、Tzu-Lan Yeh、Roman Belle、Holger Kramer、Anthony Tumber、Rasheduzzaman Chowdhury、Emily Flashman、Jasmin Mecinović、Christopher J. Schofield

  DOI：10.1039/c8cc07706a

  日期：——

  We describe covalently binding modulators of the activity of human prolyl hydroxylase domain 2 (PHD2) and studies towards a strategy for photocapture of PHD2 substrates.

  我们描述了共价结合的人类脯氨酸羟化酶结构域2（PHD2）活性调节剂，并进行了研究，以制定一种用于光捕获PHD2底物的策略。
• Synthesis and fluorescence properties of benzoxazole-1,4-dihydropyridine dyads achieved by a multicomponent reaction
  作者：Ricardo Ferreira Affeldt、Antônio César de Amorim Borges、Dennis Russowsky、Fabiano Severo Rodembusch

  DOI：10.1039/c4nj00777h

  日期：——

  Photoactive ESIPT dyads with a high Stokes' shift were obtained by a multicomponent one-pot Hantzsch synthesis.

  具有高Stokes位移的光活性ESIPT双子通过多组分一锅Hantzsch合成获得。
• Synthesis and Characterisation of Polymer‐Anchored Oxidovanadium(IV) Complexes and Their Use for the Oxidation of Styrene and Cumene
  作者：Mannar R. Maurya、Umesh Kumar、P. Manikandan

  DOI：10.1002/ejic.200601130

  日期：2007.6

  PS-H2fsal-ea (IV), PS-H2fsal-pa (V) and PS-H2fsal-amp (VI) gave the oxidovanadium(IV) complexes, PS-[VO(fsal-ea)·DMF] (4), PS-[VO(fsal-pa)·DMF] (5) and PS-[VO(fsal-amp)·DMF] (6), respectively. The corresponding neat complexes [VO(fsal-ea)]2 (1), [VO(fsal-pa)]2 (2) and [VO(fsal-amp)]2 (3) have also been similarly prepared. These complexes all exhibit a medium intensity band between 964 and 993 cm–1 in their

  Schiff 碱 H2fsal-ea (I)、H2fsal-pa (II) 和 H2fsal-amp (III)，分别衍生自 3-甲酰基水杨酸和 2-氨基乙醇、3-氨基丙醇和 2-氨基-2-甲基丙醇，分别具有通过共价键连接到用 5% 二乙烯基苯交联的氯甲基化聚苯乙烯。在二甲基甲酰胺 (DMF) 中用 [VO(acac)2] 处理后，这些聚合物锚定的配体 PS-H2fsal-ea (IV)、PS-H2fsal-pa (V) 和 PS-H2fsal-amp (VI) 得到氧化钒(IV) 复合物，PS-[VO(fsal-ea)·DMF] (4), PS-[VO(fsal-pa)·DMF] (5) 和 PS-[VO(fsal-amp)·DMF] ( 6) 分别。相应的纯配合物 [VO(fsal-ea)]2 (1)、[VO(fsal-pa)]2 (2) 和 [VO(fsal-amp)]2 (3) 也已类似地制备。由于
• Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors
  申请人：——

  公开号：US20040220206A1

  公开（公告）日：2004-11-04

  The present invention provides compounds of Formula (I): 1 or a stereoisomer or pharmaceutically acceptable salt or hydrate form thereof, wherein the variables A, B, L 1 , L 2 , X 1 , X 2 , X 3 , X 4 and W are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了Formula (I)的化合物：1或其立体异构体或药用可接受的盐或水合物形式，其中变量A、B、L1、L2、X1、X2、X3、X4和W如本文所定义。Formula (I)的化合物可作为凝血级联和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂，例如凝血酶、因子Xa、因子XIa、因子IXa、因子VIIa和/或血浆激肽。具体地，涉及具有选择性因子XIa抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用这些药物组合物治疗血栓栓塞性和/或炎症性疾病的方法。
• The synthesis and evaluation of benzofuranones as β-Lactamase substrates
  作者：S Adediran

  DOI：10.1016/s0968-0896(00)00345-x

  日期：2001.5

  These compounds were prepared by lactonization of the corresponding, appropriately substituted phenylglycines. The latter compounds were prepared by either the Strecker or the Bücherer-Berg method. The benzofuran-2-ones were less stable in aqueous solution than the analogous acyclic phenaceturate esters but comparably stable to analogous benzopyran-2-ones. They differed from the latter compounds however

  已经合成了6-和7-羧基-3-苯基乙酰胺基-3H-1-苯并呋喃-2-酮作为潜在的β-内酰胺酶底物和/或抑制剂。这些化合物通过相应地适当取代的苯基甘氨酸的内酯化制备。后一种化合物是通过Strecker或Bücherer-Berg方法制备的。苯并呋喃-2-酮在水溶液中的稳定性不及类似的无环苯乙酸酯，但与类似的苯并吡喃-2-酮相比则稳定。但是，它们与后一种化合物的区别在于，呋喃-2-酮的C-3氢与内酯羰基相邻，具有明显的酸性。7-羧基-3-苯基乙酰胺基-3H-1-苯并呋喃-2-酮在pH 7.5下以烯醇化物的形式大量存在。呋喃-2-酮是β-内酰胺酶的底物，其反应性与类似的无环苯乙酸盐非常相似。但是，它们不是DD肽酶抑制剂，因此不太可能具有抗生素活性。讨论了这些观察的结构基础。

表征谱图